Hassan Asadi
Esmaeel Toni
Haleh Ayatollahi- 1Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
- 2Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
- 3Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran
Background: Recently, the use of telemedicine technology has increased due to the Covid-19 pandemic. Cardiovascular diseases management is one of the areas that has benefited from using this technology. This study aimed to identify the applications of telemedicine for cardiovascular diseases management during the Covid-19 pandemic.
Methods: This scoping study was conducted in 2023. Various databases, including PubMed, Web of Science, Scopus, the Cochrane Library, Ovid, CINAHL, ProQuest, and IEEE Xplore along with Google Scholar were searched and all related quantitative, qualitative, and mixed-method studies published in English between 2020 and 2022 were included. Finally, the required data were extracted, and the findings were reported narratively.
Results: A total of 17 articles were included in this study. The results showed that teleconsultation via telephone and videoconferencing were the most common used technologies. Telemedicine helped to improve clinical impacts such as patient health status and quality of care, and reduced hospitalizations and re-admission rates compared to in-person visits. The non-clinical impact included reducing waiting time, in-person visits, and healthcare costs during the Covid-19 pandemic.
Conclusion: The Covid-19 pandemic has led to an increased use of telemedicine technology, especially for patients with cardiovascular diseases. As teleconsultation and telemonitoring are useful for cardiovascular diseases management and regular examinations, future research should investigate how these technologies can be improved and used for a wider population.
1 Introduction
Cardiovascular diseases are one of the main causes of worldwide death (1, 2). Nearly half of all deaths in high-income countries and about 28% of deaths in low- and middle-income countries are caused by cardiovascular diseases (3, 4). According to the literature, approximately 23.6 million people will die due to cardiovascular diseases by 2030 (2, 5–7) Therefore, many interventions have been carried out to reduce the burden of diseases and the number of deaths, to provide the necessary training for better prevention and treatment, and to use new technologies such as telemedicine for better patient-provider interactions (6–8).
In late 2019, when the world faced with the Covid-19 pandemic (9), patients with cardiovascular diseases were more at risk of adverse consequences caused by infections and complications of the Covid-19 disease (10, 11). Moreover, the pandemic caused significant cardiometabolic risk factors that could worsen the prognosis for cardiovascular patients. The cytokine storm and visceral obesity were among these risk factors. The cytokine storm, a hyperactive immune response triggered by Covid-19, coud lead to severe inflammation and multi-organ failure, particularly affecting the cardiovascular system. Visceral obesity, a condition characterized by excess fat around the internal organs, was identified as a major risk factor for severe Covid-19 outcomes, including heart failure and atherosclerosis (12).
Therefore, the application of telemedicine technology increased, as this technology helped with reducing the spread of the disease by decreasing patient attendance in the crowded places such as hospitals (13). In addition, the technology was easy to use and provided the patients with low-cost services (14).
The use of this technology for cardiovascular patients during the Covid-19 pandemic minimized the risk of disease transmission at primary care, provided optimal treatment, and prevented the deterioration of the clinical conditions. It also led to early signs monitoring of heart failure and reduced unnecessary hospitalizations (15–17).
Molinari et al.'s study showed that the use of telecardiography technology for cardiovascular patient management led to reduction in non-emergency and emergency visits by half and a quarter, respectively (18). In another study, Ajibade et al. found that the use of telemedicine services can be effective in pre-and post-operative care and for treating patients with cardiovascular diseases during the Covid-19 pandemic (9).
Although, several review studies have been conducted on the use of telemedicine technology for treating patients with cardiovascular diseases during the Covid-19 pandemic (9, 19–22), few studies have investigated different types of technologies, services, and clinical and non-clinical impact of telemedicine on cardiovascular diseases management during the Covid-19 pandemic. Therefore, the present study aimed to identify the applications of telemedicine for cardiovascular diseases management during the Covid-19 pandemic.
2 Methods
In this scoping review, Arksey and O'Malley's framework was used (23). A scoping review can help to provide a comprehensive overview of the research topic and to combine the results of different study types. In addition, conducting a scoping review allows for faster and more cost-effective resolution of the gaps in the existing knowledge and the extraction of essential data elements from different studies.
2.1 Stage 1: identify the research question
The starting point for developing a search strategy in review studies is identifying the research question. Therefore, the research question for the present study was generated as follows:
What were the applications of telemedicine technology for cardiovascular diseases management during the COVID-19 pandemic?
2.2 Stage 2: identifying of relevant studies
To identify relevant studies, search strategies were developed and eight databases including PubMed, Web of Science, Scopus, the Cochrane Library, Ovid, IEEE Xplore, ProQuest, CINAHL, and the Google Scholar search engine were searched for studies that were published in English between 1st June 2020 and 31th December 2022. The search strategy consisted of the three main terms “Covid-19”, “telemedicine”, and “cardiovascular diseases” which were combined using AND/OR logical operators (Appendix I). To increase reliability, the reference list of the included studies and their citations were also examined.
2.3 Stage 3: selection of the studies
To select the relevant studies, specific inclusion and exclusion criteria were set. All original articles published in English that used different types of research methodologies including quantitative, qualitative, and mixed-methods approaches to evaluate the use of telemedicine interventions for cardiovascular diseases management during the Covid-19 pandemic were included in this study.
Review articles, letters to the editor, protocols, and studies that did not reported the use of telemedicine technology for cardiovascular diseases management as an intervention were excluded from the current study. In addition, studies that were not published in English, did not report clinical or non-clinical impacts, and their full-texts were not available were all excluded from the review.
2.4 Stage 4: data charting
After searching articles, the retrieved studies were entered into the EndNote software. Then, duplicates were removed, and the remaining articles were evaluated based on the relevance of their titles and abstracts to the objective of the present study. Subsequently, the full texts of the eligible studies was obtained and examined. Both authors (HA and ET) independently screened the articles and resolved any disagreements through discussion. Any disagreements were discussed and solved with the help of the third author (HA). The screening process of articles was undertaken based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (24).
Having read the full texts of the included studies, the required data were extracted using a data extraction form. The data included the name/s of the author/s, year of publication, country, study objective, research methodology, type of telemedicine services, type of telemedicine technology, the impact of technology, and a summary of the main results.
2.5 Stage 5: collecting, summarizing, and reporting the results
The extracted data were tabulated, summarized, and reported narratively. Results were reported by categorizing studies according to the type of telemedicine services, type of technology, and clinical and non-clinical impact.
3 Results
Initially, 401 papers were retrieved. After removing duplicated and completing the screening process, 17 articles met the inclusion criteria and were selected for further review (7, 15, 16, 18, 25–37). Figure 1 shows the process of selecting articles based on the PRISMA diagram.
Figure 1. Selecting papers based on the PRISMA-ScR checklist (24).
3.1 Characteristics of the selected studies
Most of the included studies were conducted in the USA (n = 5) (25, 26, 29, 30, 32). Other studies were conducted in Italy (n = 3) (18, 28, 36), India (n = 2) (7, 33), Australia (n = 1) (35), Czech Republic (n = 1) (16), England (n = 1) (27), Portugal (n = 1) (15), Thailand (n = 1) (34), China (n = 1) (37) and Egypt (n = 1) (31). Four studies were published in 2022, and 13 related studies were published in 2021. Most of the studies used quantitative methods and included before-after studies (n = 6) (7, 16, 18, 28, 32, 34), retrospective cohort studies (n = 2) (29, 30), analytic cross-sectional studies (n = 3) (26, 35, 36), descriptive cross-sectional research (n = 2) (33, 37), randomized controlled trial studies (n = 2) (25, 31), and a prospective cohort study (n = 1) (15). Only one study used a mixed-methods exploratory design (27). Table 1 shows more details about the included studies.
Table 1. Summary of the studies.
3.2 Types of telemedicine services
The results showed that teleconsultation (n = 10) (7, 15, 26, 28–30, 33, 35–37), televisit (n = 2) (18, 29), telemonitoring (n = 2) (25, 27, 32), telegenetics (n = 1) (32), telerehabilitation (n = 1) (16), and teleclinic (n = 1) (34) services were used to manage cardiovascular diseases during the Covid-19 pandemic.
Teleconsultation was used as the most common telemedicine services for a variety of cardiovascular diseases, such as heart failure (7, 15, 26, 30, 33, 36), congenital heart disease (28, 37), acute myocardial infarction (31) and outpatient cardiac patients with emergencies (35) during the Covid-19 pandemic.
3.3 Types of telemedicine technologies
According to the results, telephone consultations (n = 9) (7, 15, 26, 28, 32–36), videoconferencing (n = 7) (26, 29–31, 34, 35) via platforms such as CardioClick (29, 30), Heartbeat Health (26), and Zoom (31), mobile applications (n = 3) (16, 25, 27), wireless sensors (n = 2) (16, 27), tele-electrocardiogram (n = 1) (18), messenger (n = 1) (37), text messaging (n = 1) (15), and email (n = 1) (15) were used to manage patients with cardiovascular diseases during the Covid-19 pandemic.
These technologies had several advantages. Mobile applications helped to improve patient health status (25, 27) and cardiorespiratory fitness (16). Videoconferencing was effective in reducing time for being visited (29) and number of re-hospitalizations (26). Telephone-based consultations facilitated hospitalization (33, 34), caring for heart transplantation (34), and providing nursing services (36).
3.4 The impact of using telemedicine services
The impact of using telemedicine services on cardiovascular diseases management were divided into two categories: clinical impact (e.g., reducing re-admissions rates, improving patient condition, etc.), and non-clinical impact (e.g., reducing waiting times and increasing satisfaction, awareness, etc.). The details of these categories are presented in the below sections.
3.4.1 Clinical impact
Patients with cardiovascular diseases benefited from using telemedicine services during the Covid-19 pandemic. It improved clinical symptoms (27, 29), low-density lipoprotein cholesterol (29), shortness of breath (28, 37), palpitations (28), and limb edema (28). The use of telemedicine also enhanced the timeliness of respiratory infection diagnosis (37). Batalik et al. reported that telerehabilitation improved cardiac and respiratory functions and reduced walking test times in patients with coronary artery diseases (16). Teleconsultation also aided cardiac rehabilitation for patients with acute myocardial infarction (31). Hospitalization rates were reduced using telemedicine services compared to in-person visits (7, 15, 26, 33).
Moreover, patient consultations with physicians increased through telemedicine (28, 30, 32, 34). Televisits were more effective than in-person visits (31), and teleclinic services decreased heart transplant surgeries for patients with heart failure (34). Overall, telemedicine improved physical activity, mental wellness, anxiety reduction, nutritional well-being, prevention of weight gain, and immunity to Covid-19 (25, 27, 37). It also facilitated medication dosage control (34), medication adherence (31), smoking cessation (31), follow-up quality (35), and health status monitoring (36) for patients with cardiovascular diseases.
3.4.2 Non-clinical impact
Several studies demonstrated that the implementation of teleconsultation services has resulted in increasing satisfaction among physicians, nurses (31, 33), and patients (33). In addition, teleconsultation services can efficiently decrease waiting times (29), and the time required for in-person visits (7, 18, 31). Some studies showed that using telemedicine services during the Covid-19 pandemic had some advantages over in-person consultations. These included reducing the workload of physicians (29, 31), saving travel costs (31), preventing readmissions (26, 34), and improving healthcare quality (16).
3.5 Synthesis
Overall, the results of this study indicated that telephone consultation (n = 9, 53%) and videoconferencing (n = 7, 41.1%) were the most common tools for providing telemedicine services. CardioClick, Heartbeat Health, and Zoom were the most commonly used platforms for videoconferencing. The findings also indicated that the primary non-clinical impacts of telemedicine services for patients with cardiovascular diseases during the Covid-19 pandemic included the reduction of in-person visits and healthcare providers' workload. The clinical impacts included decreasing re-admission rates, improving vital signs, and quality of care.
4 Discussion
The present study examined the applications of telemedicine for cardiovascular diseases management during the Covid-19 pandemic. According to the results, teleconsultations and televisits were the most used services and the main tools were telephone and videoconferencing. The use of telemedicine had some clinical and non-clinical impacts which could improve quality of care and cardiac rehabilitation, and reduce waiting times and healthcare costs.
Similar to the findings of this study, other studies have demonstrated that offering teleconsultation services, particularly for cardiovascular patients, has resulted in reducing the risk of Covid-19 infection (38). Furthermore, several studies showed that teleconsultation services have significantly improved clinical symptoms compared to the in-person consulattions (39, 40). This was an effective approach for reducing in-person visits, readmissions, and referrals. Better medication adherence, improving clinical symptoms, and easier patient follow-up during the Covid-19 pandemic were among other benefits of teleconsultations.
The results showed that televisit services during Covid-19 pandemic had a number of benefits, such as reducing the physician's workload and saving their time. Similarly, Gorodeski et al. showed that televisit services might be helpful for patients with heart failure to reduce re-hospitalization rates and to improve clinical outcomes (41). Brunettiet al. showed that using televisits and electrocardiograms reduced the duration of emergency care for patients with cardiovascular diseases (19, 42).
Regarding the technology and communication tools, telephone and videoconferencing were the most commonly used technologies for the provision of telemedicine services to the patients with cardiovascular diseases during the Covid-19 pandemic. The results of several studies showed that the use of telephone consultation was effective in providing ongoing support for maintaining and promoting behavioral health changes, medication adherence, and controlling risk factors for cardiovascular diseases (43, 44).
Moreover, telephone counseling can effectively reduce healthcare costs for cardiovascular patients (42). This type of services led to a reduction in hospital length of stay, number of referrals, and number of hospitalizations, surgeries, and emergency surgeries during the Covid-19 era (43). Similarly, the use of videoconferencing led to diagnose symptoms and treat patients as early as possible, reduce re-hospitalizations, decrease emergency care visits, and save healthcare costs (42, 44, 45). Idris et al. showed that videoconferencing can be effective for patients with heart failure in scheduling weekly visits (46).
The use of mobile-based applications was another approach to manage cardiovascular diseases. For instance, Sua et al. demonstrated that self-management interventions using mobile-based applications were correlated with a decrease in blood pressure among individuals with cardiovascular conditions (47). Similarly, Rawstorn et al. found that telemedicine and telecardiac rehabilitation were effective in controlling diastolic blood pressure, reducing low-density lipoprotein cholesterol, and improving respiratory capacity (48).
However, the findings of Huang et al.'s research indicated that the implementation of telemedicine interventions did not yield a statistically significant correlation with enhanced cardiac rehabilitation for patients. Furthermore, it failed to induce improvements in clinical symptoms such as weight loss, blood pressure, cholesterol levels, smoking cessation, and quality of life (49).
The findings demonstrated that telemedicine and mobile phone applications were effective in reducing the hospitalization rates of patients with cardiovascular diseases during the Covid-19 pandemic. Similarly, several studies showed that telemedicine interventions effectively decreased the rate of re-admission among patients with cardiovascular diseases compared to the standard care (50–54). In contrast, some researchers reported that the implementation of telemonitoring did not have an impact on the re-admission rate of patients with heart failure (55, 56).
Improving clinical care, quality of life, and psychological well-being for patients with heart failure were other benefits of using telemedicine services during the Covid-19 pandemic. Marra et al. found that using telephone consultation and videoconferencing services was significantly effective in improving nutritional well-being in patients with cardiovascular diseases (57).
Several studies reported that using telemedicine in the management of patients with heart failure has resulted in a reduction in mortality rate (52, 58–60). Similarly, the study conducted by Gallagher et al. revealed that providing post-discharge telephone consultations can improve treatment adherence in patients with heart failure (44, 61). The results of several studies demonstrated that telephone consultation is especially helpful for the early diagnosis of cardiovascular diseases and reduces diagnostic costs (42, 52, 62). Van Dyck et al. found that using telemonitoring services decreased the number of emergency department visits and reduced 15% healthcare costs (63). Other studies reported that using telemedicine significantly improves physical activity and quality of life in patients with coronary heart disease (59, 64).
It is notable that during the Covid-19 pandemic, managing heart failure in patients with dilated cardiomyopathy (DCM) posed significant challenges that were effectively mitigated through telemedicine technologies. DCM is characterized by the heart's diminished ability to pump blood effectively, and requires continuous and comprehensive management to prevent exacerbations and hospitalizations (65). Telemedicine enabled remote management by providing tools for regular teleconsultations, which allowed healthcare providers to assess DCM symptoms, adjust treatments, and offer immediate medical advice without necessitating in-person visits (66, 67).
Telemonitoring technologies, such as wearable devices and mobile health applications, played a crucial role by continuously tracking vital signs like blood pressure, heart rate, and weight (68). These technologies facilitated early detection of worsening conditions, prompting timely medical interventions for DCM patients that prevented hospital admissions. In addition, virtual cardiac rehabilitation programs supported DCM patients in maintaining their physical activity and managing their condition during lockdowns (69, 70).
Studies showed that these telehealth interventions led to reduced hospital readmissions, improved medication adherence, and better management of heart failure symptoms. The ability to provide real-time, patient-specific care remotely proved invaluable in maintaining the health and safety of DCM patients, minimizing their exposure to Covid-19, and ensuring continuous, effective disease management (32). This approach not only addressed the immediate needs during the pandemic but also highlighted the potential for ongoing telemedicine integration in managing chronic cardiovascular diseases (71).
4.1 Limitations
This study had some limitations. The first limitation was related to the number of databases and the inclusion criteria set for the selecting the articles. In this study, certain databases were searched and only studies published in English were included. There might be other articles indexed in different databases and published in non-English languages that were not included in this study. However, the researchers believed that the main databases were searched in this study to include as many relevant articles as possible. The second limitation might be related to the type of the study which was a scoping review. Although this study helped to provide an overview of the applications of telemedicine for cardiovascular diseases management during the Covid-19 pandemic, the impact of this intervention was not measured quantitatively. Future research can focus on conducting systematic reviews and meta-analysis to identify the clinical and non-clinical impact of telemedicine using quantitative approaches.
5 Conclusion
This study investigated the application of telemedicine for cardiovascular diseases management during the Covid-19 pandemic. The findings showed the efficacy of using telemedicine for cardiovascular diseases management, especially in terms of clinical and non-clinical impacts. The results suggested the potentials of telemedicine technology for managing patients with cardiovascular diseases even in the post-Covid-19 era. Future research should concentrate on identifying practical strategies for using telemedicine in cardiovascular diseases management, considering patients' and healthcare providers' perspectives. In addition, future studies should investigate new solutions to improve the accessibility, affordability, and privacy of telemedicine services.
Author contributions
HA: Conceptualization, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. ET: Methodology, Writing – original draft, Writing – review & editing, Investigation, Validation. HA: Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
This research was funded by the Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran [1401-1-112-23017].
Acknowledgment
This research was supported by the Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. (2020) 14:247–50. doi: 10.1016/j.dsx.2020.03.013
2. Mamashli L. Telenursing in cardiovascular diseases: a critical review of systematic reviews of evidence. Iran J Med Sci. (2022) 1:20–32.
3. Yan R, Li W, Yin L, Wang Y, Bo J, Investigators PU-C. Cardiovascular diseases and risk-factor burden in urban and rural communities in high-, middle-, and low-income regions of China: a large community-based epidemiological study. J Am Heart Assoc. (2017) 6:e004445. doi: 10.1161/JAHA.116.004445
4. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. (2020) 41:1798–800. doi: 10.1093/eurheartj/ehaa231
5. World Health Organization. Cardiovascular diseases (CVD). (2022). Available online at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html (accessed Febuary 20, 2022).
6. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease Control Priorities in Developing Countries. Washington, D.C.: World Bank Publications (2006).
7. Sachdeva S, Saxena A, Shakya S, Ramakrishnan S, Gupta SK, Kothari SS. Changing pattern of congenital heart disease care during COVID-19 pandemic. Indian J Pediatr. (2021) 88:899–904. doi: 10.1007/s12098-021-03702-y
8. Jaén-Extremera J, Afanador-Restrepo DF, Rivas-Campo Y, Gómez-Rodas A, Aibar-Almazán A, Hita-Contreras F, et al. Effectiveness of telemedicine for reducing cardiovascular risk: a systematic review and meta-analysis. J Clin Med. (2023) 12(3):841. doi: 10.3390/jcm12030841
9. Ajibade A, Younas H, Pullan M, Harky A. Telemedicine in cardiovascular surgery during COVID-19 pandemic: a systematic review and our experience. J Card Surg. (2020) 35:2773–84. doi: 10.1111/jocs.14933
10. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. (2020) 75:2352–71. doi: 10.1016/j.jacc.2020.03.031
11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
12. Quagliariello V, Bonelli A, Caronna A, Conforti G, Iovine M, Carbone A, et al. SARS-CoV-2 infection and cardioncology: from cardiometabolic risk factors to outcomes in cancer patients. Cancers (Basel). (2020) 12(11):3316. doi: 10.3390/cancers12113316
13. Keshvardoost S, Bahaadinbeigy K, Fatehi F. Role of telehealth in the management of COVID-19: lessons learned from previous SARS, MERS, and ebola outbreaks. Telemed J E Health. (2020) 26:850–2. doi: 10.1089/tmj.2020.0105
14. Hollander JE, Carr BG. Virtually perfect? Telemedicine for COVID-19. N Engl J Med. (2020) 382:1679–81. doi: 10.1056/NEJMp2003539
15. Afonso Nogueira M, Ferreira F, Raposo AF, Mónica L, Simões Dias S, Vasconcellos R, et al. Impact of telemedicine on the management of heart failure patients during coronavirus disease 2019 pandemic. ESC Heart Fail. (2021) 8:1150–5. doi: 10.1002/ehf2.13157
16. Batalik L, Konecny V, Dosbaba F, Vlazna D, Brat K. Cardiac rehabilitation based on the walking test and telerehabilitation improved cardiorespiratory fitness in people diagnosed with coronary heart disease during the COVID-19 pandemic. Int J Environ Res Public Health. (2021) 18:2241. doi: 10.3390/ijerph18052241
17. Colbert GB, Venegas-Vera AV, Lerma EV. Utility of telemedicine in the COVID-19 era. Rev Cardiovasc Med. (2020) 21:583–7. doi: 10.31083/j.rcm.2020.04.188
18. Molinari G, Brunetti ND, Nodari S, Molinari M, Spagna G, Ioakim M, et al. Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy. Intern Emerg Med. (2021) 16:1191–6. doi: 10.1007/s11739-020-02564-0
19. Brunetti ND, Dellegrottaglie G, De Gennaro L, Di Biase M. Telemedicine pre-hospital electrocardiogram for acute cardiovascular disease management in detainees: an update. Eur Res Telemed. (2015) 4:25–32. doi: 10.1016/j.eurtel.2015.02.002
20. Farabi H, Rezapour A, Jahangiri R, Jafari A, Rashki Kemmak A, Nikjoo S. Economic evaluation of the utilization of telemedicine for patients with cardiovascular disease: a systematic review. Heart Fail Rev. (2020) 25:1063–75. doi: 10.1007/s10741-019-09864-4
21. Kuan PX, Chan WK, Fern Ying DK, Rahman MAA, Peariasamy KM, Lai NM, et al. Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis. Lancet Digit Health. (2022) 4:e676–e91. doi: 10.1016/S2589-7500(22)00124-8
22. Meinhart F, Stütz T, Sareban M, Kulnik ST, Niebauer J. Mobile technologies to promote physical activity during cardiac rehabilitation: a scoping review. Sensors. (2021) 21:65. doi: 10.3390/s21010065
23. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. (2005) 8:19–32. doi: 10.1080/1364557032000119616
24. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. (2018) 169:467–73. doi: 10.7326/M18-0850
25. Brewer LC, Jenkins S, Hayes SN, Kumbamu A, Jones C, Burke LE, et al. Community-based, cluster-randomized pilot trial of a cardiovascular mHealth intervention: rationale, design, and baseline findings of the FAITH! trial. Am Heart J. (2022) 247:1–14. doi: 10.1016/j.ahj.2022.01.009
26. Friedman DM, Goldberg JM, Molinsky RL, Hanson MA, Castaño A, Raza SS, et al. Avirtual cardiovascular care program for prevention of heart failure readmissions in a skilled nursing facility population: retrospective analysis. JMIR Cardio. (2021) 5:e29101. doi: 10.2196/29101
27. Frith G, Carver K, Curry S, Darby A, Sydes A, Symonds S, et al. Changes in patient activation following cardiac rehabilitation using the active + me digital healthcare platform during the COVID-19 pandemic: a cohort evaluation. BMC Health Serv Res. (2021) 21:1363. doi: 10.1186/s12913-021-07363-7
28. Grandinetti M, Di Molfetta A, Graziani F, Delogu AB, Lillo R, Perri G, et al. Telemedicine for adult congenital heart disease patients during the first wave of COVID-19 era: a single center experience. J Cardiovasc Med. (2021) 22:706–10. doi: 10.2459/JCM.0000000000001195
29. Kalwani NM, Osmanlliu E, Parameswaran V, Qureshi L, Dash R, Heidenreich PA, et al. Changes in telemedicine use and ambulatory visit volumes at a multispecialty cardiovascular center during the COVID-19 pandemic. J Telemed Telecare. (2024) 30(3):543–8. doi: 10.1177/1357633X211073428
30. Kalwani NM, Wang KM, Johnson AN, Deb JD, Gold T, Maddukuri AK, et al. Application of the quadruple aim to evaluate the operational impact of a telemedicine program. Healthcare. (2021) 9:100593. doi: 10.1016/j.hjdsi.2021.100593
31. Kamel H, Hafez MS, Bastawy I. Telemedicine improves the short-term medical care of acute ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Front Cardiovasc Med. (2021) 8:693731. doi: 10.3389/fcvm.2021.693731
32. Liang LW, Kalia I, Latif F, Waase MP, Shimada YJ, Sayer G, et al. The use of telemedicine in cardiogenetics clinical practice during the COVID-19 pandemic. Mol Genet Genomic Med. (2022) 10:e1946. doi: 10.1002/mgg3.1946
33. Mohan B, Singh B, Singh K, Naik N, Roy A, Goyal A, et al. Impact of a nurse-led teleconsultation strategy for cardiovascular disease management during COVID-19 pandemic in India: a pyramid model feasibility study. BMJ open. (2022) 12:e056408. doi: 10.1136/bmjopen-2021-056408
34. Puwanant S, Sinphurmsukskul S, Krailak L, Nakaviroj P, Boonbumrong N, Siwamogsatham S, et al. The impact of the coronavirus disease and tele-heart failure clinic on cardiovascular mortality and heart failure hospitalization in ambulatory patients with heart failure. PLoS One. (2021) 16:e0249043. doi: 10.1371/journal.pone.0249043
35. Rowe SJ, Paratz ED, Fahy L, Prior DL, MacIsaac AI. Telehealth in Australian cardiology: insight into factors predicting the use of telephone versus video during the COVID-19 pandemic. Intern Med J. (2021) 51:1229–35. doi: 10.1111/imj.15444
36. Russo V, Cassini R, Caso V, Donno C, Laezza A, Naddei M, et al. Nursing teleconsultation for the outpatient management of patients with cardiovascular disease during COVID-19 pandemic. Int J Environ Res Public Health. (2021) 18:2087. doi: 10.3390/ijerph18042087
37. Zhang QL, Xie WP, Lei YQ, Cao H, Chen Q. Telemedicine usage via WeChat for children with congenital heart disease preoperatively during COVID-19 pandemic: a retrospective analysis. Int J Qual Health Care. (2021) 33(2):mzab066. doi: 10.1093/intqhc/mzab066
38. Barrios V, Cosín-Sales J, Bravo M, Escobar C, Gámez JM, Huelmos A, et al. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the spanish society of cardiology. Revista Espanola de Cardiologia (English ed). (2020) 73:910–8. doi: 10.1016/j.recesp.2020.06.027
39. Iliuță L, Andronesi AG, Rac-Albu M, Furtunescu FL, Rac-Albu ME, Scafa-Udriște A, et al. Challenges in caring for people with cardiovascular disease through and beyond the COVID-19 pandemic: the advantages of universal access to home telemonitoring. Healthcare. (2023) 11:1727. doi: 10.3390/healthcare11121727
40. Iliuta L, Andronesi AG, Rac-Albu M, Rac-Albu ME, Scafa-Udriste A, Moldovan H, et al. Telemedicine for optimizing secondary prevention in coronary artery bypass grafting patients during COVID-19 pandemic. Healthcare (Basel, Switzerland). (2023) 11(11):1590. doi: 10.3390/healthcare11111590
41. Gorodeski EZ, Moennich LA, Riaz H, Jehi L, Young JB, Tang WHW. Virtual versus in-person visits and appointment no-show rates in heart failure care transitions. Circ Heart Fail. (2020) 13:e007119. doi: 10.1161/CIRCHEARTFAILURE.120.007119
42. Joubert J, Nkomazana O, Mompati K, Joubert L, Preux PM, La Croix P, et al. A community survey of cardiovascular risk factors in an urban population in Botswana exploring potential for telemedicine. Eur Res Telemed. (2014) 3:95–103. doi: 10.1016/j.eurtel.2014.07.001
43. Irewall AL, Ulvenstam A, Graipe A, Ögren J, Mooe T. Nurse-based secondary preventive follow-up by telephone reduced recurrence of cardiovascular events: a randomised controlled trial. Sci Rep. (2021) 11:15628. doi: 10.1038/s41598-021-94892-0
44. Yu M, Chair SY, Chan CWH, Choi KC. A health education booklet and telephone follow-ups can improve medication adherence, health-related quality of life, and psychological status of patients with heart failure. Heart Lung. (2015) 44:400–7. doi: 10.1016/j.hrtlng.2015.05.004
45. Kotb A, Cameron C, Hsieh S, Wells G. Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): a systematic review and network meta-analysis. PLoS One. (2015) 10:e0118681. doi: 10.1371/journal.pone.0118681
46. Idris S, Degheim G, Ghalayini W, Larsen TR, Nejad D, David S. Home telemedicine in heart failure: a pilot study of integrated telemonitoring and virtual provider appointments. Rev Cardiovasc Med. (2015) 16:156–62. doi: 10.3909/ricm0760
47. Sua YS, Jiang Y, Thompson DR, Wang W. Effectiveness of mobile phone-based self-management interventions for medication adherence and change in blood pressure in patients with coronary heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Nurs. (2020) 19:192–200. doi: 10.1177/1474515119895678
48. Rawstorn JC, Gant N, Direito A, Beckmann C, Maddison R. Telehealth exercise-based cardiac rehabilitation: a systematic review and meta-analysis. Heart (British Cardiac Society). (2016) 102(15):1183–92. doi: 10.1136/heartjnl-2015-308966
49. Huang K, Liu W, He D, Huang B, Xiao D, Peng Y, et al. Telehealth interventions versus center-based cardiac rehabilitation of coronary artery disease: a systematic review and meta-analysis. Eur J Prev Cardiol. (2015) 22:959–71. doi: 10.1177/2047487314561168
50. Bart NK, Emmanuel S, Friits-Lamora R, Larkins E, Kotlyar E, Muthiah K, et al. Rapid triage and transition to telehealth for heart transplant patients in the COVID-19 pandemic setting. J Telemed Telecare. (2023) 15:1357633X231151714. doi: 10.1177/1357633X231151714
51. Benson GA, Sidebottom A, Sillah A, Boucher JL, Miedema MD, Knickelbine T, et al. Reach and effectiveness of the HeartBeat connections telemedicine pilot program. J Telemed Telecare. (2018) 24:216–23. doi: 10.1177/1357633X17692723
52. Kruse CS, Soma M, Pulluri D, Nemali NT, Brooks M. The effectiveness of telemedicine in the management of chronic heart disease—a systematic review. JRSM open. (2017) 8:2054270416681747. doi: 10.1177/2054270416681747
53. Salzano A, D'Assante R, Stagnaro FM, Valente V, Crisci G, Giardino F, et al. Heart failure management during the COVID-19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre. Eur J Heart Fail. (2020) 22:1048–50. doi: 10.1002/ejhf.1911
54. Sosa Liprandi MI, Elfman M, Zaidel EJ, Viniegra M, Sosa Liprandi Á. Impact of a telemedicine program after a heart failure hospitalization on 12 months follow-up events. Curr Probl Cardiol. (2023) 48:101624. doi: 10.1016/j.cpcardiol.2023.101624
55. Frederix I, Vanderlinden L, Verboven AS, Welten M, Wouters D, De Keulenaer G, et al. Long-term impact of a six-month telemedical care programme on mortality, heart failure readmissions and healthcare costs in patients with chronic heart failure. J Telemed Telecare. (2019) 25:286–93. doi: 10.1177/1357633X18774632
56. Negarandeh R, Zolfaghari M, Bashi N, Kiarsi M. Evaluating the effect of monitoring through telephone (tele-monitoring) on self-care behaviors and readmission of patients with heart failure after discharge. Appl Clin Inform. (2019) 10:261–8. doi: 10.1055/s-0039-1685167
57. Ventura Marra M, Lilly CL, Nelson KR, Woofter DR, Malone J. A pilot randomized controlled trial of a telenutrition weight loss intervention in middle-aged and older men with multiple risk factors for cardiovascular disease. Nutrients. (2019) 11:229. doi: 10.3390/nu11020229
58. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet (London, England). (2018) 392:1047–57. doi: 10.1016/S0140-6736(18)31880-4
59. Oldridge N, Pakosh M, Grace SL. A systematic review of recent cardiac rehabilitation meta-analyses in patients with coronary heart disease or heart failure. Future Cardiol. (2019) 15:227–49. doi: 10.2217/fca-2018-0085
60. Zhu Y, Gu X, Xu C. Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. (2020) 25:231–43. doi: 10.1007/s10741-019-09801-5
61. Gallagher BD, Moise N, Haerizadeh M, Ye S, Medina V, Kronish IM. Telemonitoring adherence to medications in heart failure patients (TEAM-HF): a pilot randomized clinical trial. J Card Fail. (2017) 23:345–9. doi: 10.1016/j.cardfail.2016.11.001
62. Coley N, Rosenberg A, van Middelaar T, Soulier A, Barbera M, Guillemont J, et al. Older adults’ reasons for participating in an eHealth prevention trial: a cross-country, mixed-methods comparison. J Am Med Dir Assoc. (2019) 20:843–9.e5. doi: 10.1016/j.jamda.2018.10.019
63. Van Dyck W, Vértes G, Palaniappan M, Gassull D, Jain P, Schulthess D, et al. Acute coronary syndrome: what is the cost-effectiveness of prevention, point-of-care technology and telemonitoring? Health Policy Technol. (2012) 1:173–7. doi: 10.1016/j.hlpt.2012.07.002
64. Reid RD, Morrin LI, Beaton LJ, Papadakis S, Kocourek J, McDonnell L, et al. Randomized trial of an internet-based computer-tailored expert system for physical activity in patients with heart disease. Eur J Prev Cardiol. (2012) 19:1357–64. doi: 10.1177/1741826711422988
65. Seferović PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, et al. Heart failure in cardiomyopathies: a position paper from the heart failure association of the European Society of Cardiology. Eur J Heart Fail. (2019) 21:553–76. doi: 10.1002/ejhf.1461
66. Chen CK, Grignani RT, Lim YP, Quek SC. The impact of COVID-19 on the practice of pediatric cardiology: a narrative review. Med Pediatr. (2021) 5. doi: 10.21037/pm-21-64
67. Iliuță L, Andronesi AG, Rac-Albu M, Rac-Albu ME, Scafa-Udriște A, Moldovan H, et al. Importance of tissue Doppler evaluation in dilated cardiomyopathy: the value of diastolic filling pattern as a prognostic predictor. J Cardiovasc Dev Dis. (2023) 10(6):237. doi: 10.3390/jcdd10060237
68. Mariani S, Schöde A, Homann K, Feueriegel S, Nöth S, Warnke K, et al. Telemonitoring and care program for left ventricular assist device patients during COVID-19 outbreak: a European experience. Asaio J. (2021) 67:973–81. doi: 10.1097/MAT.0000000000001526
69. Chockalingam P, Natarajan V, Sekar T, Anantharaman R, Yusuf MM, Gunasekaran S, et al. Effectiveness of a home-based cardiovascular disease prevention program during the COVID-19 pandemic. J Clin Prev Cardiol. (2022) 11:37–43. doi: 10.4103/jcpc.jcpc_53_21
70. Iliuta L, Andronesi AG, Panaitescu E, Rac-Albu ME, Scafa-Udriște A, Moldovan H. Challenges for management of dilated cardiomyopathy during COVID-19 pandemic-A telemedicine application. J Clin Med. (2022) 11(24):7411. doi: 10.3390/jcm11247411
71. Hammersley DJ, Buchan RJ, Lota AS, Mach L, Jones RE, Halliday BP, et al. Direct and indirect effect of the COVID-19 pandemic on patients with cardiomyopathy. Open Heart. (2022) 9(1):e001918. doi: 10.1136/openhrt-2021-001918
Appendix
Appendix I: Search strategies
Keywords: telemedicine, telehealth, disease management, cardiovascular diseases, COVID-19
Citation: Asadi H, Toni E and Ayatollahi H (2024) Application of telemedicine technology for cardiovascular diseases management during the COVID-19 pandemic: a scoping review. Front. Cardiovasc. Med. 11:1397566. doi: 10.3389/fcvm.2024.1397566
Received: 7 March 2024; Accepted: 1 August 2024;
Published: 12 August 2024.
Edited by:
Junjie Xiao, Shanghai University, ChinaReviewed by:
Luminita Iliuta, Carol Davila University of Medicine and Pharmacy, RomaniaVincenzo Quagliariello, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Italy
© 2024 Asadi, Toni and Ayatollahi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haleh Ayatollahi, ayatollahi.h@iums.ac.ir
†ORCID:
Haleh Ayatollahi
orcid.org/0000-0003-3974-3648